SLN124 + Placebo
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-transfusion-dependent Thalassemia
Conditions
Non-transfusion-dependent Thalassemia, Low Risk Myelodysplastic Syndrome, Very-Low Risk Myelodysplastic Syndrome
Trial Timeline
Apr 14, 2021 → May 23, 2023
NCT ID
NCT04718844About SLN124 + Placebo
SLN124 + Placebo is a phase 1 stage product being developed by Silence Therapeutics for Non-transfusion-dependent Thalassemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04718844. Target conditions include Non-transfusion-dependent Thalassemia, Low Risk Myelodysplastic Syndrome, Very-Low Risk Myelodysplastic Syndrome.
What happened to similar drugs?
0 of 1 similar drugs in Non-transfusion-dependent Thalassemia were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05499013 | Phase 1/2 | Active |
| NCT04718844 | Phase 1 | Completed |
| NCT04559971 | Phase 1 | Completed |
Competing Products
2 competing products in Non-transfusion-dependent Thalassemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo Matching Mitapivat + Mitapivat | Agios Pharmaceuticals | Phase 3 | 38 |
| SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo | Silence Therapeutics | Phase 1 | 11 |